ARTC (Art Technology Acquisition Corp. Class A Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by ARTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2014-03-12 | BARBARA D BOYAN | Director | MIXED | — | — |
| 2014-02-28 | Richard W. Rew II | Senior VP & General Counsel | MIXED | — | — |
| 2014-02-05 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | Sell | — | — |
| 2014-01-10 | BARBARA D BOYAN | Director | MIXED | — | — |
| 2014-01-10 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | MIXED | — | — |
| 2014-01-10 | JEAN WOLOSZKO | Chief Tech Officer & SVP R&D | MIXED | — | — |
| 2014-01-06 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | MIXED | — | — |
| 2013-12-20 | BARBARA D BOYAN | Director | MIXED | — | — |
| 2013-12-20 | JEAN WOLOSZKO | Chief Technology Officer & SVP | MIXED | — | — |
| 2013-12-18 | JAMES L PACEK | Sr VP,Global Markets & Sales | MIXED | — | — |
| 2013-10-31 | JEAN WOLOSZKO | Chief Technology Officer & SVP | Sell | — | — |
| 2013-10-08 | JAMES L PACEK | Sr VP, Strategic Business Unit | Sell | — | — |
| 2013-06-21 | SCOTT SCHAFFNER | SVP & GM SPORTS MEDICINE | A | — | — |
| 2013-06-21 | Richard W. Rew II | Senior VP & General Counsel | A | — | — |
| 2013-06-21 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | MIXED | — | — |
| 2013-06-21 | DAVID FITZGERALD | Board of Directors | A | — | — |
| 2013-06-21 | JEAN WOLOSZKO | Chief Technical Officer & SVP | A | — | — |
| 2013-06-21 | JAMES L PACEK | Sr VP, Strategic Business Unit | A | — | — |
| 2013-06-21 | Todd Newton | SVP, CFO & COO | A | — | — |
| 2013-05-29 | TORD LENDAU | Director | MIXED | — | — |
| 2013-05-29 | PETER WILSON | Director | MIXED | — | — |
| 2013-05-24 | GREGORY BELINFANTI | Director | A | — | — |
| 2013-05-24 | Christian Ahrens | Director | A | — | — |
| 2013-05-24 | OEP AC Holdings, LLC | 10%+ Owner | A | — | — |
| 2013-05-23 | TORD LENDAU | Director | A | — | — |
| 2013-05-23 | BARBARA D BOYAN | Director | A | — | — |
| 2013-05-23 | JAMES FOSTER | Director | A | — | — |
| 2013-05-23 | PETER WILSON | Director | A | — | — |
| 2013-05-23 | TERRENCE E GEREMSKI | Director | A | — | — |
| 2013-01-09 | JAMES G FOSTER | Director | Sell | — | — |
| 2012-12-31 | JAMES G FOSTER | Director | M | — | — |
| 2012-11-15 | DAVID FITZGERALD | Board of Directors | MIXED | — | — |
| 2012-08-09 | JAMES G FOSTER | Director | MIXED | — | — |
| 2012-07-06 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | Sell | — | — |
| 2012-05-30 | TERRENCE E GEREMSKI | Director | A | — | — |
| 2012-05-30 | PETER WILSON | Director | MIXED | — | — |
| 2012-05-29 | BARBARA D BOYAN | Director | A | — | — |
| 2012-05-29 | Christian Ahrens | Director | A | — | — |
| 2012-05-29 | JAMES G FOSTER | Director | A | — | — |
| 2012-05-29 | GREGORY BELINFANTI | Director | A | — | — |
| 2012-05-29 | TORD LENDAU | Director | MIXED | — | — |
| 2012-05-29 | One Equity Partners III, L.P. | 10%+ Owner | A | — | — |
| 2012-03-01 | JAMES L PACEK | Sr VP, Strategic Business Unit | MIXED | — | — |
| 2012-03-01 | BRUCE PROTHRO | Chief Regulatory Officer & SVP | A | — | — |
| 2012-03-01 | Richard W. Rew II | Senior VP & General Counsel | MIXED | — | — |
| 2012-03-01 | Todd Newton | SVP, CFO & COO | MIXED | — | — |
| 2012-03-01 | DAVID FITZGERALD | Board of Directors | MIXED | — | — |
| 2012-03-01 | Andrew Miclot | SVP & GM ENT Tech | MIXED | — | — |
| 2012-03-01 | JEAN WOLOSZKO | CTO and SVP | A | — | — |
| 2012-03-01 | SCOTT SCHAFFNER | SVP & GM SPORTS MEDICINE | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Board of Directors | 199,763 | — |
| — | President and CEO | 112,524 | — |
| — | Director | 61,370 | — |
| — | Director | 58,070 | — |
| — | Director | 52,848 | — |
| — | Chief Tech Officer & SVP R&D | 49,024 | — |
| — | SVP, CFO & COO | 47,214 | — |
| — | Director | 42,241 | — |
| — | Director | 37,725 | — |
| — | Sr. Vice President, Operations | 37,105 | — |
| — | Senior VP & General Counsel | 36,893 | — |
| — | Chief Regulatory Officer & SVP | 36,883 | — |
| — | President, International | 34,909 | — |
| — | Sr VP,Global Markets & Sales | 27,428 | — |
| — | Director | 24,454 | — |
| — | SVP & GM SPORTS MEDICINE | 22,454 | — |
| — | Senior VP and CFO | 20,898 | — |
| — | Sr VP of Strategic Business | 11,756 | — |
| — | SVP & GM ENT Tech | 9,513 | — |
| — | Sr. VP & P of ARTC Sports | 8,984 | — |
| — | Chief Accounting Officer | 8,790 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARTC quote page; the site-wide leaderboard is on the insider transactions hub.